MIRA
INFORM REPORT
|
Report Date : |
14.05.2011 |
IDENTIFICATION DETAILS
|
Name : |
EVEREST PHARMACEUTICALS |
|
|
|
|
Registered Office : |
Plot No. 124, Industrial Triangle, |
|
|
|
|
Country : |
|
|
|
|
|
Year of Establishment : |
2003 |
|
|
|
|
Com. Reg. No.: |
RF/ICT/6685 |
|
|
|
|
Legal Form : |
Partnership Business. |
|
|
|
|
Line of Business : |
Manufacture & Marketing of
Pharmaceutical Products. |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Small company |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2010
|
Country Name |
Previous Rating (30.09.2010) |
Current Rating (31.12.2010) |
|
|
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Business Name
EVEREST PHARMACEUTICALS
Full Address
|
Registered
Address & Factory |
|
Plot
No. 124, Industrial Triangle, |
|
Tel # |
92 (51) 4493496, 4493497 |
|
Fax # |
92 (51) 4491924 |
Short Description Of Business
|
a. |
Nature of
Business |
Engaged in
Manufacture & Marketing of Pharmaceutical Products |
|
b. |
Year Established |
2003 |
|
c. |
Registration # |
RF/ICT/6685 |
Legal Status
|
Subject Company was established as a
Partnership business in 2003 |
Details of Managing Partner /
Partners
|
Names |
Address |
Occupation |
Designation |
|
Mr. Sajjad Munir Mr. Hassan Ahmed |
Plot
No. 124, Industrial Triangle, Plot
No. 124, Industrial Triangle, |
Business Business |
Managing Partner Partner |
Associates
Subsidiary
None
Associated Companies
- Do -
Product/Services
Engaged in manufacture & marketing of
Pharmaceutical Products by its brand names of AZIOTIC, BAVARIN, CEFOLUK,
CINVOLOX, CLOSFIN, CORTICOZOLE, COSARTAN, DEFLOQUIN, DERMAFUSE-H, DINFRADIN, DOMCIN,
DROXATIL, ELUXIT, EVDON, EVEPRAM, EVEQUIN, GYTON, LAPPANTOX, LEXIDEX, MEFIXIM,
MICTRACIN, NOXICAM, OHAB, ROXITIN, RUMPO, RUMSO, SHEXIB, SICKNOR, TAVIT,
TICOBAL, TIZMIN, VELSAID, WINSLET, XALVO, XEOXCIN, XEXAB
Number of Employees
65
Annual Sales Volume (In Pak
Rupees)
|
Year |
In Pak Rupees |
|
2009 |
80,000,000/- (Estimated) |
Trade Suppliers (Foreign)
(1) LAKE CHEMICAL
LTD.,
(2) KUNSHAN CHEMICAL CO LTD,
(3) CHANGZHOU SUNCHEM CHEMICAL CO LTD,
Distribution Network
|
Mainly in all major cities of |
Bankers
(1) Habib Bank Limited,
(2)
Askari Bank Limited,
(3)
Standard Chartered
(4)
Bank Alfalah Limited,
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 84.85 |
|
|
1 |
Rs. 138.60 |
|
Euro |
1 |
Rs. 120.50 |
Comments
Subject Company was established in 2003 and is engaged in manufacture & marketing of Pharmaceutical Products. Overall reputation is normal. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.44.91 |
|
|
1 |
Rs.73.06 |
|
Euro |
1 |
Rs.64.03 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.